Could a drug combo spare bladder cancer patients from surgery?
NCT ID NCT07643519
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, given before surgery to people with muscle-invasive bladder cancer or upper tract urothelial carcinoma. The goal is to see if the drugs can shrink or eliminate the cancer enough that some bladder cancer patients may avoid bladder removal, and to improve outcomes for upper tract cancer patients before standard surgery. The study will enroll 39 adults and measure how many achieve a complete response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enfortumab vedotin and pembrolizumab (combination immunotherapy and antibody-drug conjugate)
What this could lead to
If successful, this could allow some bladder cancer patients to avoid bladder removal surgery, preserving their bladder, and improve outcomes for upper tract cancer patients before surgery.
What could go wrong
This is a small, early-phase trial (39 participants) with no results yet. The combination may cause significant side effects, and not all patients will respond well enough to avoid surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.